Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities

Publication Date: 11/06/2017

Download Publication

Key Findings

• The demands on tissue specimens from diagnostic stains and PD-L1 testing may leave little remaining for genomic profiling
• Gaps in genomic biomarker testing can be overcome with new technologies

"Liquid biopsy could help rescue patients who cannot receive genotype testing because of insufficient tissue."

Martin E. Gutierrez, MD

John Theurer Cancer Center

Study Overview

In this prospective analysis of 193 advanced cancer patients profiled with the Guardant360 assay, the objective response rate for patients in the NSCLC arm who were matched to targeted therapy was 87%.

The disease control rate was 100%.

Points for your practice

• This prospective study demonstrated the clinical utility of using ctDNA to guide treatment selection in advanced cancer patients

• A quarter of the patients in the NSCLC cohort were matched to targeted therapy

• Median overall survival more than doubled (31.8 vs. 12.7 months) with targeted therapy compared to non-targeted cytotoxic therapy

You may also
be interested in...

Specification Sheet

Guardant360^® CDx provides guideline-recommended genomic results in 7 days from a routine blood draw, eliminating the need to solely rely on tissue testing.

View Publication Download material

Jama Oncology

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

View Publication View Publication